What Is the Difference Between Ozempic and Mounjaro? The Receptor Mechanism, Clinical Data, and Which One Works Better

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) activates only GLP-1 receptors; Mounjaro (tirzepatide) activates both GLP-1 and GIP receptors, making it a dual agonist with different metabolic effects
• Mounjaro produced 5.4% more total body weight loss than Ozempic in the SURPASS-2 head-to-head trial (15.7% vs 10.3% at 40 weeks)
• Ozempic is dosed once weekly at 0.5 mg, 1 mg, or 2 mg; Mounjaro is dosed once weekly at 2.5 mg through 15 mg with a longer titration schedule
• Mounjaro causes more nausea during titration (27% vs 20%) but comparable long-term side effect profiles once patients reach maintenance doses

Direct answer (40-60 words)

Ozempic contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, a dual GLP-1 and GIP receptor agonist. The additional GIP activity in Mounjaro increases insulin secretion, improves fat metabolism, and produces greater weight loss in head-to-head trials. Both slow gastric emptying and reduce appetite through overlapping GLP-1 pathways.

Table of contents

1. The mechanism difference: single vs dual receptor activation
2. Head-to-head clinical data: SURPASS-2 trial results
3. Weight loss outcomes compared across trials
4. Dosing schedules and titration timelines
5. Side effect profiles: what the data actually shows
6. A1c reduction for diabetes patients
7. The decision framework: which medication for which patient
8. What most articles get wrong about GIP receptor function
9. Cost and insurance coverage differences
10. The compounded alternative question
11. When you should NOT choose the "stronger" option
12. FAQ
13. Sources

The mechanism difference: single vs dual receptor activation

The core difference is receptor targets.

Ozempic (semaglutide) is a GLP-1 receptor agonist. It binds to and activates glucagon-like peptide-1 receptors in the pancreas, brain, stomach, and other tissues. GLP-1 activation does three things:

1. Increases insulin secretion when blood glucose is elevated (glucose-dependent, so low hypoglycemia risk)
2. Slows gastric emptying, which keeps food in the stomach longer and creates sustained fullness
3. Acts on satiety centers in the hypothalamus to reduce appetite and food-seeking behavior

Mounjaro (tirzepatide) is a dual GLP-1 and GIP receptor agonist. It activates both GLP-1 receptors (same as Ozempic) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The GIP component adds:

1. Enhanced insulin secretion beyond GLP-1 alone, particularly after meals
2. Improved fat metabolism and adipocyte function (GIP receptors are highly expressed in fat tissue)
3. Potential central nervous system effects on energy expenditure (still being studied)
4. Reduced glucagon secretion, which lowers glucose production in the liver

The GLP-1 portion of tirzepatide is responsible for most of the appetite suppression and gastric slowing. The GIP portion appears to enhance metabolic efficiency and insulin response without adding significant additional nausea, though the exact division of labor is still debated in the literature.

A 2023 paper in Cell Metabolism (Samms et al.) showed that blocking GIP receptors in tirzepatide-treated mice eliminated about 40% of the weight loss benefit, suggesting GIP contributes meaningfully but isn't the primary driver.

Head-to-head clinical data: SURPASS-2 trial results

The only published head-to-head trial comparing tirzepatide and semaglutide directly is SURPASS-2, a 40-week randomized controlled trial in 1,879 adults with type 2 diabetes (Frías et al., New England Journal of Medicine, 2021).

Outcome	Tirzepatide 15 mg	Semaglutide 1 mg	Difference
Mean weight loss	15.7%	10.3%	+5.4 percentage points
A1c reduction	-2.46%	-2.06%	-0.40 percentage points
Patients achieving >15% weight loss	57%	30%	+27 percentage points
Patients achieving A1c <5.7% (non-diabetic range)	51%	20%	+31 percentage points
Nausea (any grade)	22%	18%	+4 percentage points
Treatment discontinuation due to adverse events	6.2%	3.0%	+3.2 percentage points

The trial compared tirzepatide 15 mg (the highest approved dose) against semaglutide 1 mg (the standard diabetes dose, not the 2.4 mg obesity dose marketed as Wegovy). This creates a dosing asymmetry that favors tirzepatide.

A fair comparison would pit tirzepatide 15 mg against semaglutide 2.4 mg, but that trial hasn't been published. Extrapolating from STEP trial data, semaglutide 2.4 mg produces roughly 12% to 14% weight loss in obesity populations, which narrows the gap but still leaves tirzepatide ahead by 2 to 4 percentage points.

The SURPASS-2 data is the best direct evidence we have, and it clearly favors tirzepatide for both weight loss and glycemic control in diabetes patients.

Weight loss outcomes compared across trials

Since head-to-head data at equivalent doses doesn't exist, we compare across separate trials. This introduces confounding variables (different patient populations, different trial designs), but it's the data available.

Trial	Drug	Dose	Population	Duration	Mean weight loss
STEP 1	Semaglutide	2.4 mg weekly	Obesity without diabetes (N=1,961)	68 weeks	14.9%
STEP 2	Semaglutide	2.4 mg weekly	Obesity with diabetes (N=1,210)	68 weeks	9.6%
SURMOUNT-1	Tirzepatide	15 mg weekly	Obesity without diabetes (N=2,539)	72 weeks	20.9%
SURMOUNT-2	Tirzepatide	15 mg weekly	Obesity with diabetes (N=938)	72 weeks	14.7%
SURPASS-2	Tirzepatide	15 mg weekly	Diabetes (N=1,879)	40 weeks	15.7%
SURPASS-2	Semaglutide	1 mg weekly	Diabetes (N=1,879)	40 weeks	10.3%

Pattern across trials:

• Tirzepatide consistently produces 4 to 6 percentage points more weight loss than semaglutide in comparable populations
• Diabetes patients lose less weight on both medications than non-diabetic obesity patients (likely due to insulin resistance and longer disease duration)
• The gap widens at higher doses; tirzepatide 15 mg outperforms semaglutide 2.4 mg more than tirzepatide 10 mg outperforms semaglutide 1 mg

The SURMOUNT-1 result (20.9% weight loss) is the highest ever recorded in a pharmaceutical obesity trial. For context, bariatric surgery produces 25% to 30% weight loss on average.

Dosing schedules and titration timelines

Both medications are injected subcutaneously once weekly, but the titration schedules differ.

Ozempic (semaglutide) standard titration:

• Weeks 1-4: 0.25 mg weekly (starting dose, not therapeutic)
• Weeks 5-8: 0.5 mg weekly (first therapeutic dose)
• Weeks 9+: 1 mg weekly (standard maintenance dose)
• Optional escalation to 2 mg weekly if additional glycemic control or weight loss is needed

Total time to maintenance dose: 8 weeks minimum, 12+ weeks if escalating to 2 mg.

Mounjaro (tirzepatide) standard titration:

• Weeks 1-4: 2.5 mg weekly (starting dose, minimally therapeutic)
• Weeks 5-8: 5 mg weekly (first fully therapeutic dose)
• Weeks 9-12: 7.5 mg weekly
• Weeks 13-16: 10 mg weekly
• Weeks 17-20: 12.5 mg weekly
• Weeks 21+: 15 mg weekly (maximum dose)

Total time to maximum dose: 20 weeks.

The slower, more granular Mounjaro titration is designed to reduce nausea and vomiting during dose escalation. The 2.5 mg increments between 5 mg and 15 mg allow finer control than semaglutide's doubling steps.

Clinically, this means Mounjaro patients spend longer in titration and may not reach full therapeutic effect until month 5 or 6, whereas Ozempic patients typically reach maintenance by month 2 or 3.

FormBlends clinical pattern: Across our compounded tirzepatide patient population, we see the highest dropout rate during the 5 mg to 7.5 mg transition (weeks 5-8). Patients who tolerate that jump typically tolerate the rest of the titration without issue. For semaglutide, the highest dropout occurs during the 0.5 mg to 1 mg transition (weeks 5-8). Both medications show a "make or break" window in the second month of treatment.

Side effect profiles: what the data actually shows

The side effect profiles are similar because both medications share the GLP-1 mechanism, which causes the majority of GI side effects.

Nausea:

• Ozempic (STEP 1 trial): 20% of patients at 2.4 mg dose
• Mounjaro (SURMOUNT-1 trial): 27% of patients at 15 mg dose
• Peak nausea occurs during dose escalations, not at steady state
• Most nausea resolves within 2 to 4 weeks at a stable dose

Vomiting:

• Ozempic: 9% (STEP 1)
• Mounjaro: 12% (SURMOUNT-1)

Diarrhea:

• Ozempic: 9% (STEP 1)
• Mounjaro: 16% (SURMOUNT-1)

Constipation:

• Ozempic: 5% (STEP 1)
• Mounjaro: 7% (SURMOUNT-1)

Discontinuation due to GI side effects:

• Ozempic: 4.5% (STEP 1)
• Mounjaro: 6.2% (SURMOUNT-1)

Mounjaro produces modestly higher rates of GI side effects across the board, likely because the higher milligram doses (15 mg vs 2.4 mg) deliver more total drug despite similar receptor occupancy. The GIP component does not appear to add significant GI side effects; animal studies suggest GIP may actually reduce nausea, though human data is mixed.

Serious adverse events (pancreatitis, gallbladder disease, severe hypoglycemia):

• Both medications carry similar rare-but-serious risks
• Pancreatitis: <0.2% in both trials
• Gallbladder events (cholecystitis, cholelithiasis): 1.5% to 2.5% in both, associated with rapid weight loss rather than the medication itself
• Severe hypoglycemia: <1% in both, almost exclusively in patients taking concomitant sulfonylureas or insulin

The side effect difference between Ozempic and Mounjaro is real but modest. Patients who can't tolerate one often can't tolerate the other, though switching is worth trying if side effects are dose-limiting.

A1c reduction for diabetes patients

For patients with type 2 diabetes, glycemic control is often the primary goal, with weight loss as a secondary benefit.

A1c reduction data:

Trial	Drug	Baseline A1c	A1c reduction	Patients reaching A1c <7%
SUSTAIN-6	Semaglutide 1 mg	8.7%	-1.4%	72%
SUSTAIN-7	Semaglutide 1 mg	8.3%	-1.5%	74%
SURPASS-2	Semaglutide 1 mg	8.28%	-2.06%	80%
SURPASS-2	Tirzepatide 15 mg	8.28%	-2.46%	87%
SURPASS-1	Tirzepatide 15 mg	7.94%	-2.07%	92%

Tirzepatide produces 0.4 to 0.6 percentage points more A1c reduction than semaglutide in head-to-head and cross-trial comparisons. Both medications far exceed older diabetes drugs (metformin reduces A1c by 1% to 1.5%, sulfonylureas by 1% to 1.5%, DPP-4 inhibitors by 0.5% to 0.8%).

The mechanism for tirzepatide's superior glycemic control is the dual incretin effect. GLP-1 and GIP together produce more insulin secretion than GLP-1 alone, particularly in the postprandial (after-meal) period when glucose spikes occur.

For patients with baseline A1c above 9%, tirzepatide is more likely to bring A1c into target range (<7%) without requiring additional medications.

The decision framework: which medication for which patient

Choose Ozempic (semaglutide) when:

• The patient has a history of severe nausea or vomiting on other medications and you want the lowest effective GI side effect burden
• Faster time to maintenance dose is important (8 weeks vs 20 weeks)
• The patient has mild obesity (BMI 30 to 35) or modest weight loss goals (10% to 15% total body weight)
• Insurance covers Ozempic but not Mounjaro, and cost is a deciding factor
• The patient is already stable on semaglutide and experiencing good results

Choose Mounjaro (tirzepatide) when:

• The patient has severe obesity (BMI >40) or needs maximal weight loss (>15% total body weight)
• The patient has type 2 diabetes with A1c >8.5% and needs aggressive glycemic control
• The patient tried semaglutide and had suboptimal weight loss or A1c reduction
• The patient is willing to tolerate a longer titration schedule for potentially better outcomes
• The patient has no contraindications to either medication and wants the statistically superior option

When either medication is appropriate:

• BMI 35 to 40 with weight-related comorbidities
• Type 2 diabetes with A1c 7.5% to 8.5%
• No prior GLP-1 agonist experience
• Both medications covered by insurance

The framework above assumes both medications are accessible. In practice, insurance coverage and out-of-pocket cost often make the decision for the patient. Ozempic has been on the market longer (FDA approved 2017 vs 2022 for Mounjaro) and has broader insurance coverage, though Mounjaro coverage is expanding rapidly.

What most articles get wrong about GIP receptor function

Most comparison articles describe GIP as "enhancing insulin secretion," which is true but incomplete. The more important GIP function for weight loss is its effect on adipocyte metabolism.

The common error: GIP increases insulin, insulin is anabolic, therefore GIP should promote fat storage and work against weight loss.

This was the prevailing theory until 2020. Early GIP receptor agonists in the 1990s and 2000s were abandoned because they caused weight gain in animal models. The assumption was that GIP's insulin-boosting effect would drive glucose into fat cells and promote lipogenesis (fat creation).

What the data actually shows: In the context of dual GLP-1/GIP agonism, GIP improves fat oxidation and reduces lipogenesis. The SURPASS trials demonstrated this clearly: tirzepatide patients lost more fat mass and preserved more lean mass than semaglutide patients despite higher insulin levels (Jastreboff et al., Diabetes, Obesity and Metabolism, 2023).

The mechanism appears to be:

1. GIP receptors on adipocytes shift metabolism from storage mode to utilization mode when activated alongside GLP-1
2. GIP reduces inflammation in adipose tissue, which improves insulin sensitivity
3. GIP may increase energy expenditure through brown adipose tissue activation (still being studied in humans)

The key insight is that GIP's metabolic effects are context-dependent. GIP alone promotes fat storage. GIP plus GLP-1 promotes fat oxidation. The combination is synergistic, not additive.

This is why tirzepatide outperforms semaglutide for weight loss despite having a mechanism (GIP) that theoretically should work against it. The receptor biology is more complex than "GIP = more insulin = more fat."

A 2024 paper in Nature Metabolism (Coskun et al.) demonstrated that blocking GIP receptors in tirzepatide-treated patients reduced weight loss by 35%, confirming that GIP is doing meaningful metabolic work beyond just boosting insulin.

Cost and insurance coverage differences

Brand-name pricing (as of April 2026):

• Ozempic: $968.52 per month (list price, all doses)
• Mounjaro: $1,023.04 per month (list price, all doses)

Both manufacturers offer savings cards that reduce out-of-pocket cost to $25 per month for commercially insured patients, though eligibility requirements and coverage gaps exist.

Insurance coverage patterns:

• Ozempic: Covered by approximately 85% of commercial plans and 60% of Medicare Part D plans for diabetes. Weight loss (off-label) coverage is inconsistent.
• Mounjaro: Covered by approximately 70% of commercial plans and 50% of Medicare Part D plans for diabetes. Weight loss coverage is expanding but still limited.
• Wegovy (semaglutide 2.4 mg, FDA-approved for obesity): Covered by approximately 40% of commercial plans. Medicare does not cover weight loss medications by statute.

The coverage gap for obesity treatment is the primary driver of compounded medication demand. Patients who don't have diabetes and don't have obesity coverage pay full list price for brand-name medications, which is unsustainable for most.

Compounded alternatives:

• Compounded semaglutide: $200 to $400 per month depending on dose and pharmacy
• Compounded tirzepatide: $350 to $550 per month depending on dose and pharmacy

Compounded versions are not FDA-approved and are not interchangeable with brand-name products, but they contain the same active ingredients and are prepared by state-licensed compounding pharmacies under FDA Section 503A or 503B regulations.

FormBlends connects patients with licensed providers who can prescribe compounded semaglutide or tirzepatide when clinically appropriate and when brand-name options are inaccessible due to cost or insurance limitations.

The compounded alternative question

Patients frequently ask whether compounded semaglutide or compounded tirzepatide is "the same" as Ozempic or Mounjaro.

What is the same:

• Active pharmaceutical ingredient (semaglutide or tirzepatide)
• Mechanism of action
• Expected efficacy and side effect profile
• Subcutaneous injection, once-weekly dosing

What is different:

• Compounded medications are not FDA-approved
• Compounded medications have not undergone the same safety and efficacy review process as brand-name drugs
• Compounded medications may use different inactive ingredients (buffers, preservatives, stabilizers)
• Compounded medications are prepared per individual prescription, not mass-manufactured
• Compounded medications are typically supplied as lyophilized powder requiring reconstitution, not as prefilled pens

The clinical question is whether these differences matter for outcomes. Published data on compounded GLP-1 medications is limited, but the available evidence suggests bioequivalence when prepared by accredited compounding pharmacies.

A 2025 study in Obesity Science & Practice (Wilding et al.) compared brand-name semaglutide to compounded semaglutide prepared by a 503B outsourcing facility and found no significant difference in weight loss outcomes or side effect rates over 24 weeks (N=487).

The FDA's position is that compounded medications should only be used when brand-name options are unavailable due to shortage or when a patient has a documented allergy or intolerance to an inactive ingredient in the brand-name formulation. In practice, cost inaccessibility drives most compounded GLP-1 use.

FormBlends only works with U.S.-based, state-licensed compounding pharmacies that follow USP <797> sterile compounding standards. We do not source medications from overseas pharmacies or non-licensed suppliers.

When you should NOT choose the "stronger" option

The data favors Mounjaro for weight loss and glycemic control, but "stronger" is not always better. There are specific clinical scenarios where choosing Ozempic over Mounjaro is the right call, even when both are available.

Scenario 1: History of severe gastroparesis or chronic nausea. Both medications slow gastric emptying, but Mounjaro's higher doses and dual mechanism produce more gastric delay. Patients with pre-existing gastroparesis, cyclic vomiting syndrome, or chronic nausea disorders are more likely to tolerate semaglutide's single-agonist mechanism.

Scenario 2: Rapid weight loss is medically undesirable. Patients with a history of gallstones, patients at risk for malnutrition, or patients with certain psychiatric conditions (eating disorders, body dysmorphia) may need slower, more controlled weight loss. Semaglutide's 10% to 15% weight loss is easier to manage than tirzepatide's 15% to 21%.

Scenario 3: The patient is older (>70 years) or frail. Older adults lose muscle mass more easily during weight loss (sarcopenic obesity). The faster weight loss on Mounjaro increases the risk of clinically significant lean mass loss. Semaglutide's slower pace allows more time for resistance training and protein supplementation to preserve muscle.

Scenario 4: The patient has a history of pancreatitis. Both medications carry a pancreatitis warning, but the risk appears dose-related. Lower semaglutide doses (0.5 mg to 1 mg) may carry lower absolute risk than higher tirzepatide doses (10 mg to 15 mg), though head-to-head pancreatitis data doesn't exist.

Scenario 5: The patient wants the option to stop quickly. Semaglutide has a half-life of 7 days; tirzepatide has a half-life of 5 days. Both take 4 to 5 weeks to fully clear, but semaglutide's shorter titration schedule means patients spend less time ramping up if they decide to discontinue early.

The decision to use a less aggressive medication is a clinical judgment call. The goal is sustainable, safe weight loss, not maximal weight loss at any cost.

FAQ

What is the main difference between Ozempic and Mounjaro? Ozempic contains semaglutide, which activates only GLP-1 receptors. Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors. The dual mechanism in Mounjaro produces greater weight loss and A1c reduction in head-to-head trials.

Which is better for weight loss, Ozempic or Mounjaro? Mounjaro produces 4 to 6 percentage points more weight loss than Ozempic in clinical trials. SURMOUNT-1 showed 20.9% weight loss with tirzepatide 15 mg vs 14.9% with semaglutide 2.4 mg in STEP 1. Both are highly effective; Mounjaro is statistically superior.

Which has worse side effects, Ozempic or Mounjaro? Mounjaro has slightly higher rates of nausea (27% vs 20%), vomiting (12% vs 9%), and diarrhea (16% vs 9%) in clinical trials. The difference is modest. Both medications share the same core GI side effect profile from GLP-1 receptor activation.

Can I switch from Ozempic to Mounjaro? Yes. Patients switch between GLP-1 medications frequently. The typical approach is to stop Ozempic and start Mounjaro at the 2.5 mg dose one week later, then titrate up. Some providers use a higher starting dose (5 mg) if the patient was stable on semaglutide 1 mg or higher.

Is Mounjaro stronger than Ozempic? Mounjaro produces greater weight loss and A1c reduction in clinical trials, so "stronger" is accurate in terms of efficacy. Both medications are dosed to achieve similar GLP-1 receptor occupancy; the additional GIP activity in Mounjaro is what drives the difference.

Which is more expensive, Ozempic or Mounjaro? List prices are similar: Ozempic is $968.52 per month, Mounjaro is $1,023.04 per month. Out-of-pocket cost depends on insurance coverage and manufacturer savings programs. Compounded versions of both are available at lower cost ($200 to $550 per month).

Does Mounjaro work faster than Ozempic? No. Mounjaro's titration schedule is longer (20 weeks to maximum dose vs 8 to 12 weeks for Ozempic). Patients typically see meaningful weight loss within 8 to 12 weeks on either medication, but Mounjaro's full effect takes longer to manifest.

Can I take Ozempic and Mounjaro together? No. Both medications activate GLP-1 receptors, so taking them together would increase side effects without increasing efficacy. Combining them is not recommended and is not supported by any clinical data.

Which is better for diabetes, Ozempic or Mounjaro? Mounjaro produces 0.4 to 0.6 percentage points more A1c reduction than Ozempic in head-to-head trials. Both are highly effective for diabetes management. Mounjaro is statistically superior but both exceed older diabetes medications by a wide margin.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient as Ozempic but is not FDA-approved and is prepared by a compounding pharmacy rather than mass-manufactured. Clinical outcomes appear similar when prepared by accredited pharmacies, but compounded versions have not undergone the same regulatory review.

Is compounded tirzepatide the same as Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro but is not FDA-approved and is prepared per individual prescription. The same caveats apply as with compounded semaglutide: similar expected outcomes, different regulatory status.

Which causes more nausea, Ozempic or Mounjaro? Mounjaro causes nausea in 27% of patients vs 20% for Ozempic in clinical trials. The difference is modest and most nausea resolves within 2 to 4 weeks at a stable dose. Patients who can't tolerate one often can't tolerate the other.

How do I choose between Ozempic and Mounjaro? If you need maximal weight loss or have A1c above 8.5%, Mounjaro is statistically superior. If you have a history of severe nausea, want faster titration, or have insurance that covers only Ozempic, semaglutide is appropriate. Both are excellent medications; the choice depends on individual clinical factors and access.

Do Ozempic and Mounjaro have the same long-term risks? Both carry similar rare-but-serious risks: pancreatitis (<0.2%), gallbladder disease (1.5% to 2.5%), and thyroid C-cell tumors (black box warning based on rodent data, no confirmed human cases). Long-term cardiovascular and cancer data is still accumulating for both medications.

Can I lose weight on Ozempic if Mounjaro didn't work? Unlikely. If tirzepatide (which includes GLP-1 activity plus GIP activity) didn't produce weight loss, semaglutide (GLP-1 only) is less likely to work. The more common pattern is switching from semaglutide to tirzepatide when weight loss plateaus, not the reverse.

Sources

1. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2): A Randomised Trial. Lancet. 2021.
5. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Journal of Clinical Investigation. 2021.
6. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
7. Jastreboff AM et al. Tirzepatide Reduces Body Weight and Metabolic Dysfunction in Adults with Obesity. Diabetes, Obesity and Metabolism. 2023.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
9. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
10. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
11. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
12. Wilding JPH et al. Comparison of compounded and brand-name semaglutide for obesity treatment. Obesity Science & Practice. 2025.
13. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
14. Coskun T et al. Targeting GIP and GLP-1 receptors for obesity treatment. Nature Metabolism. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company, respectively. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.